

# INDEX TO VOLUME 86

- Abbot, J. V., 507-511
- Actinobacillus actinomycetem comitans* complicating thoracic actinomycosis, 341-343
- Actinobacillus* infection, thoracic, 53-54
- Adhesion molecules, 455-457
- $\beta$ -Agonists in asthma, 471-476, 477-479
- AIDS-associated lymphocytic interstitial pneumonitis, 49-52
- AIDS and mycobacterial disease, 491-494
- Air pollution, indoor, 225-235
- Airways lability predictors in the elderly, 27-32
- Airway narrowing, acute; determinants of severity, 391-396
- Airways obstruction in children, mean transit time as indicator, 301-304
- Aitken, M. L., 211-214
- Alexander, F., 485-490
- Allen, F., 121-124
- Allen, M. B., 165-166, 445
- Allergic bronchopulmonary aspergillosis, 441-442
- Alveolar-septal amyloidosis, 345-347
- Amoxycillin in lower respiratory infections, 157-160
- Amyloidosis, alveolar-septal; radiographic presentation, 345-347
- Angiotensin II, 21-26
- Anti-neutrophil cytoplasmic antibodies, 367-369
- Aprile, C., 327-333
- Arthropathy, acute, in mediastinal tuberculosis, 57-59
- Asian patients, increased admission rates in, 297-300
- Askari, A., 57-59
- Asthma
- acute, 101-104
  - acute, severe, 215-218, 495-497
  - admission rates in Asian patients, 297-300
  - $\beta$ -agonists in, 471-476, 477-479
  - airway narrowing in, 391-396
  - cardiovascular effects of therapy, 419-423
  - cortisol stress response, 495-497
  - cytokines in, 375-389
  - eosinophils in, 101-104, 375-389
  - exercise capacity, in men, 151-155
  - fenoterol, 419-423
  - functional upper airway obstruction presenting as, 513-516
  - and hyperventilation tetany, 349-351
  - hypokalaemic effects of therapy, 419-423
  - incidence in 4-11 year old children, 403-407
  - ipratropium bromide, 151-155, 215-218
  - mild, 349-351
  - nebulizer therapy, 105-108, 151-155, 215-218, 419-423
  - nedocromil sodium, 311-316
  - oral high frequency oscillations, 211-214
  - patient education and self-management, 358-359
  - peak flow measurement, 358-359
  - platelet activating factor in, 375-389
  - pulmonary function, 211-214
  - radiographer's, 167-169
  - referral to hospital specialist, 358
  - risk factor for relapse, 101-104
  - salbutamol, 419-423
  - serious, 357
  - special treatment, 357
  - steroid therapy, 105-108, 495-497, 528-529
  - terbutaline, 215-218
  - vascular factors, 179-181
  - see also Childhood asthma; Chronic asthma
- Audit, use of erythromycin, 503-505
- Austwick, P. K. C., 225-235
- Ayres, J. G., 358, 403-407
- Bacchella, L., 327-333
- Ballerin, L., 174-175
- Balter, M. S., 441-442
- Barter, C. E., 425-429
- Bass, C., 349-351
- Beasley, R., 419-423
- Bernstein, A., 317-325
- Bilton, D., 507-511
- Bleomycin-induced lung damage, 327-333
- Blood eosinophil count, 101-104
- Blundell, G., 495-497
- Boothroyd, A. E., 39-44
- Bouros, D., 219-223
- Bowker, C. M., 53-54
- Bremner, P., 419-423
- Brewis, R. A. L., 359
- Bright, P., 528
- British Association for Lung Research, Abstracts of 11th Summer Meeting, 531-543
- British Thoracic Society Research Committee, 7-13, 15-19
- Bromhexine, 157-160
- Bronchial hyperresponsiveness, 179-181
- Bronchial washings in diagnosis of invasive pulmonary aspergillosis, 243-248
- Bronchiectasis
- chest physiotherapy, 109-114
  - humidification, 109-114
  - inhaled steroids treatment, 121-124, 529
  - progression, radiological evidence, 397-401
- Bronchoalveolar lavage, diagnosis of invasive pulmonary aspergillosis, 243-248
- Brown, P. H., 495-497
- Bryan, A. J., 437-440
- Bulgheroni, A., 327-333
- Bullock, A., 105-108
- Burchard, H., 517-519
- Burgess, C., 419-423
- Bush, A., 161-164
- Butler, N., 403-407
- Campbell, B., 201-203
- Cancer
- plasma cell granuloma, 161-164
  - SCCAg as tumour marker, 201-203
  - symptomatic hypercalcaemia in, 359-360
  - synovial cell sarcoma, 357-358
  - see also Lung cancer
- Capewell, S., 485-490, 499-502
- Captopril, 21-26
- Caraco, Y., 521-523
- Carbon monoxide transfer factor in HIV-infected patients, 253-256
- Cardiovascular effects of therapy, 419-423
- Cayton, R. M., 151-155
- Chan S. L., 115-119
- Chapman, B. J., 485-490
- Chemotherapy for lymph node tuberculosis, 15-19
- Chen, Y. M., 249-251
- Chetty, M. C. P., 317-325
- Childhood asthma, incidence in 4-11 year olds, 403-407
- Children
- surgical emphysema, 529-530
  - mean transit time in, 301-304
  - pneumothorax, 529-530
  - pre-term, and inhaled sodium cromoglycate, 131-134
- Chopra, M. P., 57-59, 446-447
- Chronic airflow limitation, home nebulizer therapy, 33-38, 446-447
- Chronic asthma
- high dose steroid treatment, 105-108, 528-529
  - nedocromil sodium management, 311-316
  - steroid-dependent, 105-118, 528-529
- Chronic bronchitis, *N*-acetylcysteine treatment, 89-92
- Clancy, L., 481-484, 491-494
- Clarke, J., 121-124
- Clubbing and thermography, 257-259
- Coggon, D., 27-32
- COLD, terbutaline, inhaled, 93-96, 527-528

- Cole, P. J., 397-401  
 Computed tomography *see* CT  
 Connellan, S. J., 53-54  
 Connolly, C. K., 451-453  
 Conway, J. H., 109-114  
 COPD, acute airway narrowing, 391-396  
 Coronary artery bypass surgery, 195-199  
 Corticosteroids, 441-442  
 Cortisol stress response, 495-497  
 Costello, J., 477-479  
 Cough  
   chronic, persistent, 425-429  
   ipratropium bromide, 425-429  
   persistent, in SE England, 143-149  
 Crane, J., 419-423  
 Crisp, A., 165-166  
 Critically ill patients, oxygen transport in, 289-295  
 Crompton, G. K., 485-490, 495-497  
 Crozier, T. A., 517-519  
 CT  
   extrinsic allergic alveolitis, 135-141  
   unexplained haemoptysis, 39-44  
 Cullinan, P., 143-149  
 Cundall, D. B., 445-446  
 Cunningham, D. A., 253-356  
 Currie, D. C., 397-401  
 Cystic fibrosis  
   adolescent, 45-48  
   adult, 45-48  
   exacerbation after holidays at high altitude, 55-56  
   exercise and physiotherapy, 507-511  
   infective pulmonary exacerbation, 45-48  
   spirometry, 45-48  
 Cytokines in asthma, 375-389
- Davies, A., 125-130  
 Davies, A. J., 503-505  
 Davies, R. J., 167-169  
 de Berker, D., 61-62  
 Dilworth, J. P., 205-210  
 Disseminated tuberculosis, multiple organ failure in, 517-519  
 Dodd, M. E., 507-511  
 Donegan, C., 253-256  
 Dornely, S. M., 525-526  
 Dow, L., 27-32  
 Drennan, C., 311-316  
 Dueholm, M., 89-92  
 Dussek, J. E., 1-2  
 Dyspnoea and terbutaline, 93-96, 527-528
- Edwards, D., 39-44  
 Elborn, J. S., 121-124, 529  
 Elderly populations; respiratory symptoms as predictors of airways  
   lability, 27-32  
 Emphysema revisited (Symposium), 187-193  
 End-tidal  $PCO_2$  and hypocapnic symptoms, 335-340  
 Eosinophils, 375-389  
 Eosinophil blood count, 101-104  
 Eosinophilic granuloma, 61-62  
 Epstein-Barr virus antibodies, 49-52  
 Erslev, A. J., 261-263  
 Erythromycin, 503-505  
 Escarabill, J., 269  
 Estopa, R., 269  
 Evald, T., 89-92, 93-96, 527-528  
 Evans, J. M., 237-241  
 Evans, T. W., 289-295  
 Exercise in cystic fibrosis treatment, 507-511  
 Exercise capacity in asthma, 151-155  
 Extrinsic allergic alveolitis, 135-141
- Faragher, E. B., 225-235  
 Feldman, C., 3-5
- Fenoterol, 419-423  
 Ferraris pocket peak flow meter, 525-526  
 FEV<sub>1</sub>, 93-96, 451-453, 525-526, 527-528  
 Fitzgerald, J. M., 358-359  
 Fitzgerald, M. X., 277-282  
 Fleming, J., 253-256  
 Fleming, J. S., 109-114  
 Flower, C. D. R., 135-141  
 Fludarabine monophosphate, 261-263  
 Forman, S. J., 243-248  
 Freeman, W., 151-155  
 Freeth, M. G., 53-54  
 French, P. D., 253-256  
 Functional upper airway obstruction presenting as asthma, 513-516  
 FVC and terbutaline, 93-96, 527-528
- Galimberti, M., 327-333  
 Ganderton, D., 237-241  
 Gardner, W. N., 273-275, 335-340, 349-351  
 Giorshv, C., 257-259  
 Goldman, J. M., 33-38  
 Goswami, R., 157-160  
 Greening, A. P., 485-490, 495-497  
 Greenough, A., 97-100, 131-134
- Haemoptysis, unexplained; role of CT, 39-44  
 Han, L. Y., 397-401  
 Hansen, N.-C., 89-92  
 Hara, N., 431-436  
 Harris, J. R. W., 253-256  
 Harrison, J., 225-235  
 Healy, E., 491-494  
 Heap, D. C., 167-169  
 Herala, M., 101-104  
 Herdman, M. J., 167-169  
 Hetzel, M. R., 39-44  
 Higgenbottom, T., 105-108, 471-476, 528-529  
 Higgs, C. M. B., 367-369  
 High frequency oral oscillations, and asthma, 211-214  
 High-frequency ventilation, 125-130  
 HIV-infected patients, low carbon monoxide transfer factor in,  
   253-256  
 Hodson, M. E., 45-48, 55-56  
 Holgate, S. T., 27-32, 109-114  
 Holidays at high altitude; cystic fibrosis exacerbation, 55-56  
 Holmes, P. W., 425-429  
 Holst, P., 311-316  
 Horak, D. A., 243-248  
 Hudson, M., 301-304  
 Hudson, N. E., 125-130  
 Hughes, D. T., 525-526  
 Hughes, P., 481-484  
 Humidification, 109-114  
 Hypercalcaemia in lung cancer, 359-360  
 Hyperventilation syndromes, 273-275  
 Hyperventilation tetany due to mild asthma, 349-351  
 Hypocapnic symptoms and end-tidal  $PCO_2$  in normal subjects,  
   335-340  
 Hypokalaemic effects of therapy, 419-423  
 Hypoxic lung disease, stable, 21-26
- Immunoglobulin G subclass levels, 3-5  
 Inhaler therapy; a clinically relevant modification, 237-241  
 Inspiratory mouth pressure and respiratory muscle activity, 305-309  
 Intensive care unit; community-acquired pneumonia, 7-13  
 Intravenous drug users; AIDS and mycobacterial disease, 491-494  
 Invasive pulmonary aspergillosis; diagnosis, 243-248  
 Ipratropium bromide, 151-155, 215-218, 425-429  
 Ishida, T., 431-436
- Janson, C., 101-104  
 Javai, A., 151-155  
 John, P. J., 157-160

- Johnston, B., 121-124  
 Jolley, A. E., 503-505  
 Jones, D., 311-316  
 Jones, D. J., 283-287  
 Juniper, M. E., 1-2
- Kane, G. C., 261-263  
 Kaneko, S., 431-436  
 Kassem, N., 237-241  
 Kay, E. A., 317-325  
 Keittelmann, S., 93-96  
 Kelly, P., 481-484, 491-494  
 Kendall, S. W. H., 365-366, 437-440  
 Kortsik, C., 375-389  
 Kramer, M. R., 49-52  
 Kroegel, C., 375-389, 455-457  
 Kyi, T., 57-59
- Lange, P., 93-96  
 Large, S. R., 437-440  
 Lawton, L., 225-235  
 Lee, J., 115-119  
 Lee, P. Y., 249-251  
 Leitch, A. G., 173, 371-373, 445, 527  
 Levinson, H., 257-259  
 Levy, H., 243-248  
 Liippo, K., 359-360  
 Little, S. A., 225-235  
 Lockhart, A., 179-181  
 Low, D., 403-407  
 Lower respiratory infections  
   bromhexine treatment, 157-160  
   community-acquired, 503-505  
   erythromycin treatment, 503-505  
 Luisetti, M., 327-333  
 Lung cancer  
   primary carcinomas, 521-523  
   pulmonary tuberculoma, 431-436  
   and recurrent venous thrombosis, 521-523  
   respiratory tract epithelium and neoplasia, 531-543  
   in young patients, 499-502  
 Lung damage, bleomycin-induced, 327-333  
 Lung function, neonatal RDS, 97-100  
 Lymph node tuberculosis, 15-19  
 Lymphocytic interstitial pneumonitis associated with AIDS, 49-52
- McGarry, J., 121-124  
 McLeod, D. T., 503-505  
 McMichael, A. J., 261-263  
 Madsen, H. D., 89-92  
 Mahashur, A. A., 157-160  
 Maher, J., 481-484  
 Maltback, N., 89-92  
 Maltezas, G., 219-223  
 Manresa, F., 269  
 Mantoux test, 219-223  
 Marshall, A. J., 345-347  
 Marshall, S., 419-423  
 Matthews, A., 21-26  
 Matthys, H., 375-389, 455-457  
 Mean transit time as indicator of airways obstruction in children, 301-304  
 Mediastinal tuberculosis, acute arthropathy in, 57-59  
 Microbial indoor air pollution, 225-235  
 Millar, A. B., 39-44  
 Mitchell, D. M., 253-256  
 Monasterio, C., 269  
 Moores, C., 125-130  
 Morgan, R. A., 345-347  
 Morrison, J. F. J., 215-218  
 Mortality predictors in silicosis, 115-119  
 Moxham, J., 237-241, 349-351  
 Mucklow, E. S., 529-530
- Mucus, bronchial, effect of high-frequency ventilation on non-Newtonian properties, 125-130  
 Muers, M. F., 33-38, 215-218  
 Mulcahy, F. M., 491-494  
 Munro, N. C., 397-401, 529  
 Mycobacterial disease and AIDS, 491-494  
*Mycobacterium avium intracellulare* pulmonary infection in eosinophilic granuloma, 61-62  
 Myers, P., 297-300
- N*-acetylcysteine, 89-92  
 Nebulizer therapy  
   in asthma, 105-108, 151-155, 215-218, 419-423  
   at home, 33-38, 317-325, 446-447  
   long-term assessment, 317-325  
 Necrotizing fasciitis, 249-251  
 Nedocromil sodium  
   in chronic asthma, 311-316  
   dosage frequencies, 311-316  
 Neonatal respiratory distress syndrome, 97-100  
 Ng, G. Y., 305-309  
 Ng, T. P., 115-119  
 Nielsen, H., 89-92  
 Ninan, T., 301-304  
 Niven, R. McL., 513-516  
 Nolan, K. M., 525-526  
 Noone, P., 341-343
- Obstructive airways disease, 409-417  
 O'Connor, C. M., 277-282  
 O'Driscoll, B. R., 317-325  
 Organ failure, multiple, in disseminated tuberculosis, 517-519  
 Oropharyngeal carrier state, abnormal, 183-186  
 Ormerod, L. P., 297-300  
 Otulana, B. A., 105-108  
 Oxygen, portable, 269  
 Oxygen transport in the critically ill, 289-295  
 Øyri, A., 357
- Packe, G. E., 45-48  
 Page, C., 477-479  
 Page, R. L., 165-166  
 Pallarès, L. C. M., 289-295  
 Palmer, J. B. D., 409-417  
 Pansari, S., 403-407  
 Parry, G. W., 1-2  
 Particulate indoor air pollution, 225-235  
 Patel, J. M., 57-59  
 Paterson, I. C., 61-62  
 Patrick, H., 261-263  
 Peacock, A. J., 21-26  
 Peak flow meter, 451-453, 525-526  
 Pearce, N., 419-423  
 Pearson, S. B., 215-218, 445-446  
 PEF, 525-526  
 Penn, O. C. K. M., 195-199  
 Perng, R. P., 249-251  
 Perring, S., 109-114  
 Physiotherapy  
   in bronchiectasis, 109-114  
   in cystic fibrosis treatment, 507-511  
 Pickering, C. A. C., 225-235, 513-516  
 Pierce, R. J., 425-429  
 Pierson, D. J., 211-214  
 Pitchenik, A. E., 49-52  
 Pizzini, L., 327-333  
 Plasma cell granuloma; spontaneous arrest, 161-164  
 Platelet activating factor, 375-389  
 Pleural effusions; thoracoscopy, 437-440  
 Pneumomediastinum, 530  
 Pneumonia  
   aetiology, 7-13  
   community-acquired, 7-13, 174-175

- intensive care unit, 7-13  
 management, 7-13, 459-469  
 routine microbial investigation, 174-175  
 Pneumonitis, 'smoke-bomb', 165-166  
 Pneumothoraces from synovial cell sarcoma, 357-358  
 Pneumothorax, 529-530  
   spontaneous; surgical intervention, 1-2  
 Portable oxygen therapy, 269  
 Postoperative chest infection; problem for smokers, 205-210  
 Postoperative pulmonary function abnormalities, 195-199  
 Potena, A., 174-175  
 Prescribed respiratory diseases in the 1990s, 283-287  
 Prichard, J. S., 341-343  
 Public Health Laboratory Service, 7-13  
 Pulmonary alveolar-septal amyloidosis; radiographic presentation, 345-347  
 Pulmonary eosinophilia with systemic features, 485-490  
 Pulmonary function  
   oral high frequency oscillations, 211  
   postoperative abnormalities, 195-199  
 Pulmonary haemodynamics, 21-26  
 Pulmonary malignancy, SCCAg as tumour marker, 201-203  
 Pulmonary *Mycobacterium avium intracellulare* infection in eosinophilic granuloma, 61-62  
 Pulmonary toxicity and fludarabine monophosphate, 261-263  
 Pulmonary tuberculoma, 431-436  
 Puolijoki, H., 359-360  
 Putinati, S., 174-175  
 Putterman, C., 531-532
- Radiographer's asthma, 167-169  
 Radiographic analysis of pulmonary tuberculoma, 431-436  
 Radiological evidence of progression of bronchiectasis, 397-401  
 Rafferty, G. F., 335-340  
 Ramos, M., 49-52  
 Rea, H., 311-316  
 Rebuck, A. S., 441-442  
 Regnard, J., 279-281  
 Respiratory disease and adhesion molecules, 455-457  
 Respiratory distress syndrome, neonatal, 97-100  
 Respiratory failure, acute, and fludarabine monophosphate, 261-263  
 Respiratory muscle activity and inspiratory mouth pressure, 305-309  
 Respiratory symptoms, high incidence in 4-11 year old children, 403-407  
 Respiratory tract epithelium and neoplasia, 531-543  
 Rimmer, S. J., 55-56  
 Ring, N. J., 345-347  
 Roberts, T., 513-516  
 Rush, P. J., 257-259  
 Russell, G., 301-304
- Saisch, S. G. N., 335-340  
 Salbutamol, 419-423  
 Saldana, M. J., 49-52  
 Salmeterol, 409-417  
 Sankaran, R., 499-502  
 Sarcoidosis, 277-282  
 Sarcoma, synovial cell, 357-358  
 Sartori, S., 174-175  
 Schauer, A., 517-519  
 Schneerson, J. M., 135-141  
 Selby, C. D., 445  
 Shaheen, M. Z., 65  
 Sharma, R. R., 157-160  
 Shaw, R. J., 253-256  
 Shepherd, G. L., 409-417  
 Sheppard, M. N., 161-164  
 Shore, A., 257-259  
 Siafakas, N., 219-223  
 Sick building syndrome, 225-235  
 Silicosis, mortality predictors, 115-119  
 Simer, L., 521-523  
 Sindrup, J. H., 93-96
- Sivner, A. L., 446-447  
 Skin anergy and tuberculosis, 481-484  
 Smith, C., 3-5  
 'Smoke-bomb' pneumonitis, 165-166  
 Smokers: postoperative chest infection problems, 205-210  
 Snell, N. J. C., 357-358  
 Snook, N., 165-166  
 Sodium cromoglycate, 131-134  
 Speechly-Dick, M. E., 55-56  
 Spirometry, changes; infective pulmonary exacerbation in cystic fibrosis, 45-48  
 Sputum  
   amoxycillin levels, 157-160  
   and persistent cough, in SE England, 143-149  
   Squamous cell carcinoma antigen (SCCAg), 201-203  
 Sterk, P. J., 391-396  
 Steroid-dependent asthma, 105-108, 528-529  
 Steroids, 65  
   asthma treatment, 105-108, 495-497, 528-529  
   in bronchiectasis, 121-124, 529  
   and cortisol stress response, 495-497  
 Stewart, S., 135-141  
 Stokes, M. J., 305-309  
 Stoutenbeek, C. P., 183-186  
 Strickland, B., 397-401  
 Strunin, L., 525-526  
 Stuart, A. M., 409-417  
 Su, W. J., 249-251  
 Sudlow, M. F., 499-502  
 Sugimachi, K., 431-436  
 Sugio, K., 431-436  
 Surgical emphysema, 529-530  
 Swan, D., 358-359  
 Syabbalo, N., 173-174  
 Sydow, M., 517-519  
 Sykes, A., 403-407  
 Synovial cell sarcoma, 357-358
- Tadmor, B., 521-523  
 Tasker, V. S., 157-160  
 Taylor, E., 446-447  
 Taylor, R. J., 317-325  
 Teale, C., 33-38, 215-218, 445-446  
 Tegtmeier, B. R., 243-248  
 Terbutaline, 93-96, 215-218, 527-528  
 Tetley, T. D., 187-193  
 Thermography, use in clubbing, 257-259  
 Thomson, A. M., 446  
 Thoracic actinobacillus infection, 53-54  
 Thoracic actinomycosis complicated by *Actinobacillus actinomycetum comitans*, 341-343  
 Thoracoscopy, 365-366, 437-440  
 Thornley, P., 311-316  
 Thorshauge, H., 89-92  
 Torres, A., 183-186  
 Tracheo-bronchial clearance, 109-114  
 Transpulmonary angiotensin II formation, 21-26  
 Trevisani, L., 174-175  
 Trigg, C. J., 167-169  
 Tube thoracostomy, 249-251  
 Tuberculin skin tests, 219-223  
 Tuberculoma, pulmonary, 431-436  
 Tuberculosis  
   chemotherapy, 15-19  
   compliance with treatment, 173-174  
   contact tracing, 173, 371-373, 445-446  
   disseminated, 517-519  
   and HIV infection, 491-494  
   of lymph nodes, 15-19  
   mediastinal, 57-59  
   relapse, 173-174  
   and skin energy, 481-484  
 Tumour marker, 201-203

- Turner, M. O., 358-359  
Twentyman, O. P., 471-476  
Tyrrell, J., 341-343  
Tzanakis, N., 219-223  
Tzortzaki, E., 214-223
- Upham, J., 201-203  
Upper abdominal surgery, 205-210  
Upper airways obstruction, functional, 513-516  
Upper respiratory tract infection, 425-429
- van Belle, A. F., 195-199  
Van Saene, H. K. F., 183-186  
Varghese, G., 121-124  
Varma, N., 105-108  
Vascular factors, 179-181  
Venous thrombosis, recurrent, as presenting sign of lung cancer, 521-523  
Villani, F., 327-333  
Vincent, J. M., 135-141, 211-214  
Virchow, J. C., Jr., 375-389  
Viskum, K., 409-417
- Wadee, A., 3-5  
Wahn, U., 161-164  
Walking distance, 93-96, 527-528  
Ward, A. J. M., 237-241  
Warner, J. O., 161-164  
Wathen, C. G., 499-502  
Weatherby, H., 317-325  
Webb, A. K., 507-511, 513-516  
Weller, P. H., 403-407  
Wells, A., 311-316  
Wells, F. C., 365-366, 437-440  
Wesseling, G. J., 195-199  
White, R. J., 205-210  
Williams, J., 403-407  
Windebank, W. J., 65  
Woodhead, M. A., 459-469  
Woodman, K., 419-423  
Wouters, E. F. M., 195-199  
Wu, M. F., 249-251
- Yokota, S. B., 243-248  
Yokoyama, H., 431-436  
Yuksel, B., 97-100, 131-134
- Zwi, S., 3-5